Kate R Pawloski1, Nicole Christian1, Andrea Knezevic2, Hannah Y Wen3, Kimberly J Van Zee1, Monica Morrow1, Audree B Tadros4. 1. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, 10065, USA. 2. Biostatistics Service, Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 3. Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA. 4. Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, 300 East 66th Street, New York, NY, 10065, USA. tadrosa@mskcc.org.
Abstract
PURPOSE: Upgrade rates of conventional ADH are reported at 10-30%; however, rates for ADH bordering on DCIS (ADH-BD) are largely unknown. We examined the upgrade rate of ADH-BD and core needle biopsy (CNB) features associated with upgrade. Surgical management in patients with concurrent ipsilateral breast cancer (BC) was also examined. METHODS: From 2000 to 2018, women with CNB diagnosis of ADH-BD were prospectively identified. Women with pure ADH-BD and concurrent ipsilateral ADH-BD/BC were analyzed separately, and upgrade rates were calculated. CNB features associated with upgrade and type of surgery were examined in women with pure ADH-BD; CNB features and concurrent pathology associated with upgrade were examined in women with ipsilateral BC. RESULTS: 108/236 (46%) patients with pure ADH-BD on CNB had DCIS (40%) or invasive carcinoma (6%) on surgical excision. DCIS or invasive carcinoma was more frequently found on excision of a mass that yielded ADH-BD on biopsy than excision of calcifications (65% vs 38%; p < 0.001). The breast conservation success rate was high (80%) in patients who upgraded, despite a high re-excision rate of 46%. The upgrade rate of ADH-BD in women with concurrent ipsilateral BC was 41%. Most women (94%) with ADH-BD in the same quadrant as the BC were candidates for breast conserving surgery, with a success rate of 89%. CONCLUSION: The upgrade rate for pure ADH-BD is significantly higher than that reported for women with conventional ADH, especially in women with a mass on imaging. The upgrade rate of concurrent ipsilateral ADH-BD and BC is similarly high. Excision with a margin of normal tissue and specimen inking should be routine to minimize the need for re-excision.
PURPOSE: Upgrade rates of conventional ADH are reported at 10-30%; however, rates for ADH bordering on DCIS (ADH-BD) are largely unknown. We examined the upgrade rate of ADH-BD and core needle biopsy (CNB) features associated with upgrade. Surgical management in patients with concurrent ipsilateral breast cancer (BC) was also examined. METHODS: From 2000 to 2018, women with CNB diagnosis of ADH-BD were prospectively identified. Women with pure ADH-BD and concurrent ipsilateral ADH-BD/BC were analyzed separately, and upgrade rates were calculated. CNB features associated with upgrade and type of surgery were examined in women with pure ADH-BD; CNB features and concurrent pathology associated with upgrade were examined in women with ipsilateral BC. RESULTS: 108/236 (46%) patients with pure ADH-BD on CNB had DCIS (40%) or invasive carcinoma (6%) on surgical excision. DCIS or invasive carcinoma was more frequently found on excision of a mass that yielded ADH-BD on biopsy than excision of calcifications (65% vs 38%; p < 0.001). The breast conservation success rate was high (80%) in patients who upgraded, despite a high re-excision rate of 46%. The upgrade rate of ADH-BD in women with concurrent ipsilateral BC was 41%. Most women (94%) with ADH-BD in the same quadrant as the BC were candidates for breast conserving surgery, with a success rate of 89%. CONCLUSION: The upgrade rate for pure ADH-BD is significantly higher than that reported for women with conventional ADH, especially in women with a mass on imaging. The upgrade rate of concurrent ipsilateral ADH-BD and BC is similarly high. Excision with a margin of normal tissue and specimen inking should be routine to minimize the need for re-excision.
Entities:
Keywords:
Atypical ductal hyperplasia; Borderline lesions; Breast surgery; Ductal carcinoma in situ; Ipsilateral breast cancer; Markedly atypical ductal hyperplasia
Authors: Daniel X Choi; Anne A Eaton; Cristina Olcese; Sujata Patil; Monica Morrow; Kimberly J Van Zee Journal: Ann Surg Oncol Date: 2012-11-19 Impact factor: 5.344
Authors: Vance Sohn; Zachary Arthurs; Garth Herbert; Joren Keylock; Jason Perry; Matthew Eckert; Dean Fellabaum; Donald Smith; Tommy Brown Journal: Ann Surg Oncol Date: 2007-06-13 Impact factor: 5.344
Authors: Suzanne B Coopey; Emanuele Mazzola; Julliette M Buckley; John Sharko; Ahmet K Belli; Elizabeth M H Kim; Fernanda Polubriaginof; Giovanni Parmigiani; Judy E Garber; Barbara L Smith; Michele A Gadd; Michelle C Specht; Anthony J Guidi; Constance A Roche; Kevin S Hughes Journal: Breast Cancer Res Treat Date: 2012-11-02 Impact factor: 4.872
Authors: David J Winchester; Joel R Bernstein; Jan M Jeske; Mary H Nicholson; Elizabeth A Hahn; Robert A Goldschmidt; William G Watkin; Stephen F Sener; Malcolm B Bilimoria; Ermilio Barrera; David P Winchester Journal: Arch Surg Date: 2003-06